Long-term	long-term	O	O	O	O
efficacy	efficacy	O	O	O	O
and	and	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
high-dose	high-dose	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
for	for	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
tachycardia	tachycardia	O	DISEASE	OTHERS	I
or	or	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
fibrillation	fibrillation	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
administered	administered	O	O	O	O
to	to	O	O	O	O
154	154	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
sustained	sustained	O	O	O	O
,	,	O	O	O	O
symptomatic	symptomatic	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
tachycardia	tachycardia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
VT	vt	O	O	OTHERS	I
)	)	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
118	118	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
a	a	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
arrest	arrest	O	DISEASE	OTHERS	I
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
36	36	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
who	who	O	O	O	O
were	were	O	O	O	O
refractory	refractory	O	O	O	O
to	to	O	O	O	O
conventional	conventional	O	O	O	O
antiarrhythmic	antiarrhythmic	O	O	O	O
drugs	drugs	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
loading	loading	O	O	O	O
dose	dose	O	O	O	O
was	was	O	O	O	O
800	800	O	O	O	O
mg/day	mg/day	O	O	O	O
for	for	O	O	O	O
6	6	O	O	O	O
weeks	weeks	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
maintenance	maintenance	O	O	O	O
dose	dose	O	O	O	O
was	was	O	O	O	O
600	600	O	O	O	O
mg/day	mg/day	O	O	O	O
.	.	O	O	O	O

Sixty-nine	sixty-nine	O	O	O	O
percent	percent	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
continued	continued	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
had	had	O	O	O	O
no	no	O	O	O	O
recurrence	recurrence	O	O	O	O
of	of	O	O	O	O
symptomatic	symptomatic	O	O	O	O
VT	vt	O	O	OTHERS	I
or	or	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
fibrillation	fibrillation	O	DISEASE	OTHERS	I
(	(	O	O	O	O
VF	vf	O	O	OTHERS	I
)	)	O	O	O	O
over	over	O	O	O	O
a	a	O	O	O	O
follow-up	follow-up	O	O	O	O
of	of	O	O	O	O
6	6	O	O	O	O
to	to	O	O	O	O
52	52	O	O	O	O
months	months	O	O	O	O
(	(	O	O	O	O
mean	mean	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
standard	standard	O	O	O	O
deviation	deviation	O	O	O	O
14.2	14.2	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
8.2	8.2	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Six	six	O	O	O	O
percent	percent	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
nonfatal	nonfatal	O	O	O	O
recurrence	recurrence	O	O	O	O
of	of	O	O	O	O
VT	vt	O	O	OTHERS	I
and	and	O	O	O	O
were	were	O	O	O	O
successfully	successfully	O	O	O	O
managed	managed	O	O	O	O
by	by	O	O	O	O
continuing	continuing	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
at	at	O	O	O	O
a	a	O	O	O	O
higher	higher	O	O	O	O
dose	dose	O	O	O	O
or	or	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
addition	addition	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
conventional	conventional	O	O	O	O
antiarrhythmic	antiarrhythmic	O	O	O	O
drug	drug	O	O	O	O
.	.	O	O	O	O

One	one	O	O	O	O
or	or	O	O	O	O
more	more	O	O	O	O
adverse	adverse	O	O	OTHERS	I
drug	drug	O	O	OTHERS	I
reactions	reactions	O	O	OTHERS	I
occurred	occurred	O	O	O	O
in	in	O	O	O	O
51	51	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Adverse	adverse	O	O	O	O
effects	effects	O	O	O	O
forced	forced	O	O	O	O
a	a	O	O	O	O
reduction	reduction	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
41	41	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
discontinuation	discontinuation	O	O	O	O
of	of	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
10	10	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
most	most	O	O	O	O
common	common	O	O	O	O
symptomatic	symptomatic	O	O	O	O
adverse	adverse	O	O	O	O
reactions	reactions	O	O	O	O
were	were	O	O	O	O
tremor	tremor	O	DISEASE	OTHERS	I
or	or	O	O	O	O
ataxia	ataxia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
35	35	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
and	and	O	O	O	O
anorexia	anorexia	O	O	OTHERS	I
(	(	O	O	O	O
8	8	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
visual	visual	O	O	OTHERS	I
halos	halos	O	O	OTHERS	I
or	or	O	O	OTHERS	I
blurring	blurring	O	O	OTHERS	I
(	(	O	O	O	O
6	6	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
thyroid	thyroid	O	O	OTHERS	I
function	function	O	O	OTHERS	I
abnormalities	abnormalities	O	O	OTHERS	I
(	(	O	O	O	O
6	6	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
pulmonary	pulmonary	O	O	OTHERS	I
interstitial	interstitial	O	O	OTHERS	I
infiltrates	infiltrates	O	O	OTHERS	I
(	(	O	O	O	O
5	5	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Although	although	O	O	O	O
large-dose	large-dose	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
highly	highly	O	O	O	O
effective	effective	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
long-term	long-term	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
VT	vt	O	O	OTHERS	I
or	or	O	O	O	O
VF	vf	O	O	OTHERS	I
refractory	refractory	O	O	O	O
to	to	O	O	O	O
conventional	conventional	O	O	O	O
antiarrhythmic	antiarrhythmic	O	O	O	O
drugs	drugs	O	O	O	O
,	,	O	O	O	O
it	it	O	O	O	O
causes	causes	O	O	O	O
significant	significant	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
in	in	O	O	O	O
approximately	approximately	O	O	O	O
50	50	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
when	when	O	O	O	O
the	the	O	O	O	O
dose	dose	O	O	O	O
is	is	O	O	O	O
adjusted	adjusted	O	O	O	O
based	based	O	O	O	O
on	on	O	O	O	O
clinical	clinical	O	O	O	O
response	response	O	O	O	O
or	or	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
adverse	adverse	O	O	O	O
effects	effects	O	O	O	O
,	,	O	O	O	O
75	75	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
VT	vt	O	O	OTHERS	I
or	or	O	O	O	O
VF	vf	O	O	OTHERS	I
can	can	O	O	O	O
be	be	O	O	O	O
successfully	successfully	O	O	O	O
managed	managed	O	O	O	O
with	with	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

